Back to News
Market Impact: 0.15
Teva Pharmaceutical Industries Limited - Depositary Receipt Price Target Decreased by 19.30% to $0.11
Source: Nasdaq
Analyst InsightsAnalyst Estimates
Fintel’s aggregate analyst one-year price target for Teva Pharmaceutical Industries’ depositary receipt was revised to $0.11 per share from $0.13 on October 1, 2026, a reported decrease of 19.30%. The article excerpt provides no further context or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.20
Ticker Sentiment
TEVA-0.20
More News
- SpaceX bear flips to big bull because of AI business. Analyst now sees 70% gain
- Williams Trading cuts Deckers Outdoor stock price target on weak DTC trends
- Jefferies raises Zymeworks stock price target on Roche deal
- Truist raises United Rentals stock price target on strong margins
- Century Casinos receives Nasdaq notice for minimum market value deficiency
- GM stock analysis: cheap valuation meets falling estimates after earnings drop
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Capital IQ Alternatives for Research and Deal Work
- Research Workflows, Report Format Selection, and Interactive Synthesis